124 related articles for article (PubMed ID: 36583472)
1. Compassionate use of recombinant human IL-7-hyFc as a salvage treatment for restoring lymphopenia in patients with recurrent glioblastoma.
Ahn S; Park JS; Kim H; Heo M; Sung YC; Jeun SS
Cancer Med; 2023 Mar; 12(6):6778-6787. PubMed ID: 36583472
[TBL] [Abstract][Full Text] [Related]
2. Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy.
Kim JH; Kim YM; Choi D; Jo SB; Park HW; Hong SW; Park S; Kim S; Moon S; You G; Kang YW; Park Y; Lee BH; Lee SW
Clin Transl Immunology; 2020; 9(9):e1168. PubMed ID: 32994996
[TBL] [Abstract][Full Text] [Related]
3. rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors.
Lee M; Im SK; Baek S; Ji M; Kim M; Lee EJ; Ji ST; Ferrando-Martinez S; Wolfarth A; Lee JY; Kim D; Choi D
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471713
[TBL] [Abstract][Full Text] [Related]
4. Salvage therapy with single agent bevacizumab for recurrent glioblastoma.
Chamberlain MC; Johnston SK
J Neurooncol; 2010 Jan; 96(2):259-69. PubMed ID: 19593660
[TBL] [Abstract][Full Text] [Related]
5. Understanding the pharmacokinetic journey of Fc-fusion protein, rhIL-7-hyFc using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA.
Kim A; Oh MS; Lee GH; Song S; Byun MS; Choi D; Yu BY; Lee H
Antib Ther; 2024 Apr; 7(2):105-113. PubMed ID: 38566969
[TBL] [Abstract][Full Text] [Related]
6. From lymphopenia to restoration: IL-7 immunotherapy for lymphocyte recovery in glioblastoma.
Kim J; Choi H; Jeun SS; Ahn S
Cancer Lett; 2024 Apr; 588():216714. PubMed ID: 38369003
[TBL] [Abstract][Full Text] [Related]
7. The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas.
Kaloshi G; Diamandi P; Cakani B; Brace G; Rroji A; Petrela M
Tumori; 2015; 101(1):41-5. PubMed ID: 25702676
[TBL] [Abstract][Full Text] [Related]
8. Salvage therapy with single agent bendamustine for recurrent glioblastoma.
Chamberlain MC; Johnston SK
J Neurooncol; 2011 Dec; 105(3):523-30. PubMed ID: 21626071
[TBL] [Abstract][Full Text] [Related]
9. Fc-fused IL-7 provides broad antiviral effects against respiratory virus infections through IL-17A-producing pulmonary innate-like T cells.
Kwon DI; Park S; Jeong YL; Kim YM; Min J; Lee C; Choi JA; Choi YH; Kong HJ; Choi Y; Baek S; Lee KJ; Kang YW; Jeong C; You G; Oh Y; Im SK; Song M; Kim JK; Chang J; Choi D; Lee SW
Cell Rep Med; 2024 Jan; 5(1):101362. PubMed ID: 38232693
[TBL] [Abstract][Full Text] [Related]
10. A single administration of hIL-7-hyFc induces long-lasting T-cell expansion with maintained effector functions.
Kim S; Lee SW; Koh JY; Choi D; Heo M; Chung JY; Lee BH; Yang SH; Sung YC; Lee H; Shin EC; Park SH
Blood Adv; 2022 Dec; 6(23):6093-6107. PubMed ID: 36206199
[TBL] [Abstract][Full Text] [Related]
11. Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma.
Mendez JS; Govindan A; Leong J; Gao F; Huang J; Campian JL
J Neurooncol; 2016 Apr; 127(2):329-35. PubMed ID: 26725885
[TBL] [Abstract][Full Text] [Related]
12. Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery.
Sharma M; Schroeder JL; Elson P; Meola A; Barnett GH; Vogelbaum MA; Suh JH; Chao ST; Mohammadi AM; Stevens GHJ; Murphy ES; Angelov L
J Neurosurg; 2018 Oct; 131(2):489-499. PubMed ID: 30485180
[TBL] [Abstract][Full Text] [Related]
13. Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.
Silvani A; Lamperti E; Gaviani P; Eoli M; Fiumani A; Salmaggi A; Falcone C; Filippini G; Botturi A; Boiardi A
J Neurooncol; 2008 Apr; 87(2):143-51. PubMed ID: 17576523
[TBL] [Abstract][Full Text] [Related]
14. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
15. The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review.
Wang Y; Xing D; Zhao M; Wang J; Yang Y
PLoS One; 2016; 11(3):e0152170. PubMed ID: 27007828
[TBL] [Abstract][Full Text] [Related]
16. hIL-7-hyFc, A Long-Acting IL-7, Increased Absolute Lymphocyte Count in Healthy Subjects.
Lee SW; Choi D; Heo M; Shin EC; Park SH; Kim SJ; Oh YK; Lee BH; Yang SH; Sung YC; Lee H
Clin Transl Sci; 2020 Nov; 13(6):1161-1169. PubMed ID: 32339447
[TBL] [Abstract][Full Text] [Related]
17. Outcome of salvage treatment for recurrent glioblastoma.
Kim HR; Kim KH; Kong DS; Seol HJ; Nam DH; Lim DH; Lee JI
J Clin Neurosci; 2015 Mar; 22(3):468-73. PubMed ID: 25595963
[TBL] [Abstract][Full Text] [Related]
18. Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma.
Kim WJ; Dho YS; Ock CY; Kim JW; Choi SH; Lee ST; Kim IH; Kim TM; Park CK
J Neurooncol; 2019 Jun; 143(2):321-328. PubMed ID: 30982199
[TBL] [Abstract][Full Text] [Related]
19. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
Jakobsen JN; Urup T; Grunnet K; Toft A; Johansen MD; Poulsen SH; Christensen IJ; Muhic A; Poulsen HS
J Neurooncol; 2018 Apr; 137(2):439-446. PubMed ID: 29330749
[TBL] [Abstract][Full Text] [Related]
20. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.
Iwamoto FM; Abrey LE; Beal K; Gutin PH; Rosenblum MK; Reuter VE; DeAngelis LM; Lassman AB
Neurology; 2009 Oct; 73(15):1200-6. PubMed ID: 19822869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
